Skip to main content
Erschienen in: Breast Cancer Research 3/2002

01.06.2002 | Commentary

Liposome-based drug delivery in breast cancer treatment

verfasst von: John W Park, MD

Erschienen in: Breast Cancer Research | Ausgabe 3/2002

Einloggen, um Zugang zu erhalten

Abstract

Drug delivery systems can in principle provide enhanced efficacy and/or reduced toxicity for anticancer agents. Long circulating macromolecular carriers such as liposomes can exploit the 'enhanced permeability and retention' effect for preferential extravasation from tumor vessels. Liposomal anthracyclines have achieved highly efficient drug encapsulation, resulting in significant anticancer activity with reduced cardiotoxicity, and include versions with greatly prolonged circulation such as liposomal daunorubicin and pegylated liposomal doxorubicin. Pegylated liposomal doxorubucin has shown substantial efficacy in breast cancer treatment both as monotherapy and in combination with other chemotherapeutics. Additional liposome constructs are being developed for the delivery of other drugs. The next generation of delivery systems will include true molecular targeting; immunoliposomes and other ligand-directed constructs represent an integration of biological components capable of tumor recognition with delivery technologies.
Literatur
1.
Zurück zum Zitat Matsumura Y, Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986, 6: 193-210. Matsumura Y, Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986, 6: 193-210.
2.
Zurück zum Zitat Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multi-center trial of metastatic breast cancer. J Clin Oncol. 2001, 19: 1444-1454.PubMed Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multi-center trial of metastatic breast cancer. J Clin Oncol. 2001, 19: 1444-1454.PubMed
3.
Zurück zum Zitat Williams G, Cortazar P, Pazdur R: Developing drugs to decrease the toxicity of chemotherapy. J Clin Oncol. 2001, 19: 3439-3441.PubMed Williams G, Cortazar P, Pazdur R: Developing drugs to decrease the toxicity of chemotherapy. J Clin Oncol. 2001, 19: 3439-3441.PubMed
4.
Zurück zum Zitat Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996, 14: 2353-2364.PubMed Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996, 14: 2353-2364.PubMed
5.
Zurück zum Zitat Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996, 36: 55-63.CrossRefPubMed Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996, 36: 55-63.CrossRefPubMed
6.
Zurück zum Zitat Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, Gabizon A: Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer. 1999, 86: 72-78. 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1.CrossRefPubMed Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, Gabizon A: Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer. 1999, 86: 72-78. 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1.CrossRefPubMed
7.
Zurück zum Zitat Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol. 1997, 15: 3185-3191.PubMed Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol. 1997, 15: 3185-3191.PubMed
8.
Zurück zum Zitat Silverman P, Overmoyer B, Holder L, Tripathy D, Marrs N, Sharp-ington T: Doxil and intravenous cyclophosphamide as first line therapy for patients with metastatic breast cancer (MBC): interim results of an ongoing pilot trial [abstract]. Proc Am Soc Clin Oncol. 1999, 18: 115a- Silverman P, Overmoyer B, Holder L, Tripathy D, Marrs N, Sharp-ington T: Doxil and intravenous cyclophosphamide as first line therapy for patients with metastatic breast cancer (MBC): interim results of an ongoing pilot trial [abstract]. Proc Am Soc Clin Oncol. 1999, 18: 115a-
9.
Zurück zum Zitat Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FL, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC, Hortobagyi GN: Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol. 2001, 19: 1716-1722.PubMed Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FL, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC, Hortobagyi GN: Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol. 2001, 19: 1716-1722.PubMed
10.
Zurück zum Zitat Sparano JA, Malik U, Rajdev L, Sarta C, Hopkins U, Wolff AC: Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol. 2001, 19: 3117-3125.PubMed Sparano JA, Malik U, Rajdev L, Sarta C, Hopkins U, Wolff AC: Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol. 2001, 19: 3117-3125.PubMed
11.
Zurück zum Zitat Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A, Martin FJ: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol. 1998, 9: 711-716. 10.1023/A:1008216430806.CrossRefPubMed Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A, Martin FJ: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol. 1998, 9: 711-716. 10.1023/A:1008216430806.CrossRefPubMed
12.
Zurück zum Zitat Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed
13.
Zurück zum Zitat Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res. 1999, 5: 83-94.PubMed Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res. 1999, 5: 83-94.PubMed
14.
Zurück zum Zitat Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A: Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol. 1998, 12: 1035-1040.PubMed Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A: Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol. 1998, 12: 1035-1040.PubMed
15.
Zurück zum Zitat Li C, Price JE, Milas L, Hunter NR, Ke S, Yu DF, Charnsangavej C, Wallace S: Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res. 1999, 5: 891-897.PubMed Li C, Price JE, Milas L, Hunter NR, Ke S, Yu DF, Charnsangavej C, Wallace S: Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res. 1999, 5: 891-897.PubMed
16.
Zurück zum Zitat Park JW, Hong K, Kirpotin DB, Papahadjopoulos D, Benz CC: Immunoliposomes for cancer treatment. Adv Pharmacol. 1997, 40: 399-435.CrossRefPubMed Park JW, Hong K, Kirpotin DB, Papahadjopoulos D, Benz CC: Immunoliposomes for cancer treatment. Adv Pharmacol. 1997, 40: 399-435.CrossRefPubMed
17.
Zurück zum Zitat Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI, Papahadjopoulos D, Benz CC: Development of anti-p185HER2 immunoliposomes for cancer therapy. ProcNatl Acad Sci USA. 1995, 92: 1327-1331.CrossRef Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI, Papahadjopoulos D, Benz CC: Development of anti-p185HER2 immunoliposomes for cancer therapy. ProcNatl Acad Sci USA. 1995, 92: 1327-1331.CrossRef
18.
Zurück zum Zitat Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D: Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cell in vitro. Biochemistry. 1997, 36: 66-75. 10.1021/bi962148u.CrossRefPubMed Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D: Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cell in vitro. Biochemistry. 1997, 36: 66-75. 10.1021/bi962148u.CrossRefPubMed
19.
Zurück zum Zitat Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC: Anti-HER2 immunoliposomes for targeted therapy of human tumors. CancerLett. 1997, 118: 153-160. 10.1016/S0304-3835(97)00326-1. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC: Anti-HER2 immunoliposomes for targeted therapy of human tumors. CancerLett. 1997, 118: 153-160. 10.1016/S0304-3835(97)00326-1.
20.
Zurück zum Zitat Park JW, Kirpotin D, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC: Tumor targeting using anti-HER2 immunoliposomes. J Control Release. 2001, 74: 95-113. 10.1016/S0168-3659(01)00315-7.CrossRefPubMed Park JW, Kirpotin D, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC: Tumor targeting using anti-HER2 immunoliposomes. J Control Release. 2001, 74: 95-113. 10.1016/S0168-3659(01)00315-7.CrossRefPubMed
21.
Zurück zum Zitat Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC: Anti-HER2 immunoliposomes: enhanced anticancer efficacy due to targeted delivery. Clin Cancer Res. 2002, 8: 1172-1181.PubMed Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC: Anti-HER2 immunoliposomes: enhanced anticancer efficacy due to targeted delivery. Clin Cancer Res. 2002, 8: 1172-1181.PubMed
22.
Zurück zum Zitat Park JW, Valente N, Stauffer P, Diederich C, Kirpotin D, Leung A, Sneed P: Phase I/II study of sequential hyperthermia + Doxil® for the treatment of breast cancer metastatic to the chest wall [abstract]. Proc Am Soc ClinOncol. 2000, 19: 90a- Park JW, Valente N, Stauffer P, Diederich C, Kirpotin D, Leung A, Sneed P: Phase I/II study of sequential hyperthermia + Doxil® for the treatment of breast cancer metastatic to the chest wall [abstract]. Proc Am Soc ClinOncol. 2000, 19: 90a-
23.
Zurück zum Zitat Matteucci ML, Anyarambhatla G, Rosner G, Azuma C, Fisher PE, Dewhirst MW, Needham D, Thrall DE: Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res. 2000, 6: 3748-3755.PubMed Matteucci ML, Anyarambhatla G, Rosner G, Azuma C, Fisher PE, Dewhirst MW, Needham D, Thrall DE: Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res. 2000, 6: 3748-3755.PubMed
24.
Zurück zum Zitat Park JW, Stauffer P, Diederich C, Colbern G, Lozner A, Kirpotin D, Rugo H, Valente N, Sneed P: Hyperthermia (HT) + doxil significantly enhances drug delivery and efficacy in metastatic breast cancer of the chest wall (CW): a phase I/II study [abstract]. Proc Am Soc Clin Oncol. 2001, 20: 47a- Park JW, Stauffer P, Diederich C, Colbern G, Lozner A, Kirpotin D, Rugo H, Valente N, Sneed P: Hyperthermia (HT) + doxil significantly enhances drug delivery and efficacy in metastatic breast cancer of the chest wall (CW): a phase I/II study [abstract]. Proc Am Soc Clin Oncol. 2001, 20: 47a-
25.
Zurück zum Zitat Needham D, Anyarambhatla G, Kong G, Dewhirst MW: A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000, 60: 1197-1201.PubMed Needham D, Anyarambhatla G, Kong G, Dewhirst MW: A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000, 60: 1197-1201.PubMed
Metadaten
Titel
Liposome-based drug delivery in breast cancer treatment
verfasst von
John W Park, MD
Publikationsdatum
01.06.2002
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 3/2002
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr432

Weitere Artikel der Ausgabe 3/2002

Breast Cancer Research 3/2002 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.